Status:
UNKNOWN
Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol
Lead Sponsor:
Ultromics Ltd
Collaborating Sponsors:
Mazankowski Alberta Heart Institute
Conditions:
Cardiotoxicity
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to compare conventionally acquired Left Ventricle Ejection Fraction (LVEF) and Global Longitudinal Strain (GLS) data to Artificial Intelligence (AI) driven automated processing of 2 di...
Eligibility Criteria
Inclusion
- Normal EF and no regional wall motion abnormalities prior to starting chemotherapy treatment.
- Follow-up EF measurements available for at least 1 year during the treatment period.
- Follow-up EF measurements for at least 1 year during the treatment period.
Exclusion
- Age \< 18 years
- Inadequate image quality (as determined by the Ultromics Operators Quality Control process)
Key Trial Info
Start Date :
October 8 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2021
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04877899
Start Date
October 8 2020
End Date
November 30 2021
Last Update
September 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mazankowski Alberta Heart Institute
Edmonton, Alberta, Canada, T6G 2J2